Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H28N2O |
Molecular Weight | 336.4705 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C3=CC=CC=C3
InChI
InChIKey=PJMPHNIQZUBGLI-UHFFFAOYSA-N
InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3
Molecular Formula | C22H28N2O |
Molecular Weight | 336.4705 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/9618424Curator's Comment: Description was created based on several sources, including
https://www.addictioncenter.com/painkillers/fentanyl/ | https://www.ncbi.nlm.nih.gov/pubmed/24635521
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9618424
Curator's Comment: Description was created based on several sources, including
https://www.addictioncenter.com/painkillers/fentanyl/ | https://www.ncbi.nlm.nih.gov/pubmed/24635521
Fentanyl is a potent agonist of mu opioid receptor. It is used to relieve severe pain, such as after surgery or during cancer treatment, and breakthrough pain (flare-ups of intense pain despite round-the-clock narcotic treatment). Fentanyl is an extremely powerful analgesic, 50–100-times more potent than morphine. Fentanyl harbors massive risk for addiction and abuse regardless of its prescription form. Fentanyl abuse is especially dangerous to those without a tolerance to opioids. The substance’s already elevated risk of overdose is multiplied when someone without a tolerance abuses it.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 |
0.15 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DURAGESIC-100 Approved UseFentanyl transdermal system is a transdermal formulation of fentanyl indicated for the management of persistent, moderate to severe chronic pain in opioid-tolerant patients 2 years of age and older when a continuous, around-the-clock opioid analgesic is required for an extended period of time, and the patient cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids. Patients considered opioid-tolerant are those who are taking at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid for a week or longer. Fentanyl transdermal system contains fentanyl, a full opioid agonist. Fentanyl transdermal system is indicated for the management of persistent, moderate to severe chronic pain in opioid‑tolerant patients 2 years of age and older when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. (1) Fentanyl transdermal system is NOT intended for use as an as-needed analgesic. (1) Launch Date1990 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.91 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23497761/ |
100 μg single, intravenous dose: 100 μg route of administration: Intravenous experiment type: SINGLE co-administered: |
FENTANYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.61 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23497761/ |
400 μg single, oral transmucosal dose: 400 μg route of administration: Oral transmucosal experiment type: SINGLE co-administered: |
FENTANYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.81 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23497761/ |
400 μg single, sublingual dose: 400 μg route of administration: Sublingual experiment type: SINGLE co-administered: |
FENTANYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.76 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23497761/ |
100 μg single, intravenous dose: 100 μg route of administration: Intravenous experiment type: SINGLE co-administered: |
FENTANYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4.18 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23497761/ |
400 μg single, oral transmucosal dose: 400 μg route of administration: Oral transmucosal experiment type: SINGLE co-administered: |
FENTANYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
5.76 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23497761/ |
400 μg single, sublingual dose: 400 μg route of administration: Sublingual experiment type: SINGLE co-administered: |
FENTANYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23497761/ |
100 μg single, intravenous dose: 100 μg route of administration: Intravenous experiment type: SINGLE co-administered: |
FENTANYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
7.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23497761/ |
400 μg single, oral transmucosal dose: 400 μg route of administration: Oral transmucosal experiment type: SINGLE co-administered: |
FENTANYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
10 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23497761/ |
400 μg single, sublingual dose: 400 μg route of administration: Sublingual experiment type: SINGLE co-administered: |
FENTANYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
6 mg single, transdermal (total) Overdose Dose: 6 mg Route: transdermal Route: single Dose: 6 mg Sources: Page: p.463 |
healthy, 15 n = 1 Health Status: healthy Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.463 |
Disc. AE: Apnea, Respiratory depression... AEs leading to discontinuation/dose reduction: Apnea Sources: Page: p.463Respiratory depression Bradypnea Tachycardia Diaphoresis |
150 ug 1 times / hour multiple, transdermal Overdose Dose: 150 ug, 1 times / hour Route: transdermal Route: multiple Dose: 150 ug, 1 times / hour Sources: |
unknown, 31 n = 1 Health Status: unknown Age Group: 31 Sex: M Population Size: 1 Sources: |
Disc. AE: Respiratory arrest... AEs leading to discontinuation/dose reduction: Respiratory arrest (grade 5) Sources: |
225 ug 1 times / hour multiple, transdermal Overdose Dose: 225 ug, 1 times / hour Route: transdermal Route: multiple Dose: 225 ug, 1 times / hour Sources: Page: p.51 |
unhealthy, 32 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 32 Sex: F Population Size: 1 Sources: Page: p.51 |
Disc. AE: Syncope, Acute coronary syndrome... AEs leading to discontinuation/dose reduction: Syncope Sources: Page: p.51Acute coronary syndrome |
800 ug single, sublingual Higher than recommended Dose: 800 ug Route: sublingual Route: single Dose: 800 ug Sources: Page: p.13, 14 |
healthy, 33.4 n = 8 Health Status: healthy Age Group: 33.4 Sex: M+F Population Size: 8 Sources: Page: p.13, 14 |
Other AEs: Hypoxia, Nausea... |
800 ug single, sublingual Higher than recommended Dose: 800 ug Route: sublingual Route: single Dose: 800 ug Sources: Page: p.13, 15 |
healthy, 33.4 n = 8 Health Status: healthy Age Group: 33.4 Sex: M+F Population Size: 8 Sources: Page: p.13, 15 |
Other AEs: Somnolence... |
800 ug single, sublingual Higher than recommended Dose: 800 ug Route: sublingual Route: single Dose: 800 ug Sources: Page: p.13, 16 |
healthy, 33.4 n = 8 Health Status: healthy Age Group: 33.4 Sex: M+F Population Size: 8 Sources: Page: p.13, 16 |
Other AEs: Vomiting... |
1600 ug 1 times / 15 min multiple, sublingual (max) Highest studied dose Dose: 1600 ug, 1 times / 15 min Route: sublingual Route: multiple Dose: 1600 ug, 1 times / 15 min Sources: Page: p.309 |
unhealthy, 53±12 n = 65 Health Status: unhealthy Condition: Pain Age Group: 53±12 Sex: M+F Population Size: 65 Sources: Page: p.309 |
Disc. AE: Somnolence, Dizziness... AEs leading to discontinuation/dose reduction: Somnolence (3%) Sources: Page: p.309Dizziness (3%) Hallucinations (1.5%) Dry mouth (1.5%) Headache (1.5%) Nausea (1.5%) Vomiting (1.5%) |
5 mg single, intravenous Accidental dose Dose: 5 mg Route: intravenous Route: single Dose: 5 mg Sources: Page: p.199 |
unhealthy, 62 n = 1 Health Status: unhealthy Condition: Pain Age Group: 62 Sex: M Population Size: 1 Sources: Page: p.199 |
Disc. AE: Confusion, Restlessness... AEs leading to discontinuation/dose reduction: Confusion (acute) Sources: Page: p.199Restlessness (mild) Visual hallucinations Sweating Miosis |
200 ug 6 times / day multiple, sublingual Recommended Dose: 200 ug, 6 times / day Route: sublingual Route: multiple Dose: 200 ug, 6 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Pain Sources: Page: p.1 |
Disc. AE: Respiratory depression, Opioid abuse... AEs leading to discontinuation/dose reduction: Respiratory depression (grade 4) Sources: Page: p.1Opioid abuse |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Apnea | Disc. AE | 6 mg single, transdermal (total) Overdose Dose: 6 mg Route: transdermal Route: single Dose: 6 mg Sources: Page: p.463 |
healthy, 15 n = 1 Health Status: healthy Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.463 |
Bradypnea | Disc. AE | 6 mg single, transdermal (total) Overdose Dose: 6 mg Route: transdermal Route: single Dose: 6 mg Sources: Page: p.463 |
healthy, 15 n = 1 Health Status: healthy Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.463 |
Diaphoresis | Disc. AE | 6 mg single, transdermal (total) Overdose Dose: 6 mg Route: transdermal Route: single Dose: 6 mg Sources: Page: p.463 |
healthy, 15 n = 1 Health Status: healthy Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.463 |
Respiratory depression | Disc. AE | 6 mg single, transdermal (total) Overdose Dose: 6 mg Route: transdermal Route: single Dose: 6 mg Sources: Page: p.463 |
healthy, 15 n = 1 Health Status: healthy Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.463 |
Tachycardia | Disc. AE | 6 mg single, transdermal (total) Overdose Dose: 6 mg Route: transdermal Route: single Dose: 6 mg Sources: Page: p.463 |
healthy, 15 n = 1 Health Status: healthy Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.463 |
Respiratory arrest | grade 5 Disc. AE |
150 ug 1 times / hour multiple, transdermal Overdose Dose: 150 ug, 1 times / hour Route: transdermal Route: multiple Dose: 150 ug, 1 times / hour Sources: |
unknown, 31 n = 1 Health Status: unknown Age Group: 31 Sex: M Population Size: 1 Sources: |
Acute coronary syndrome | Disc. AE | 225 ug 1 times / hour multiple, transdermal Overdose Dose: 225 ug, 1 times / hour Route: transdermal Route: multiple Dose: 225 ug, 1 times / hour Sources: Page: p.51 |
unhealthy, 32 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 32 Sex: F Population Size: 1 Sources: Page: p.51 |
Syncope | Disc. AE | 225 ug 1 times / hour multiple, transdermal Overdose Dose: 225 ug, 1 times / hour Route: transdermal Route: multiple Dose: 225 ug, 1 times / hour Sources: Page: p.51 |
unhealthy, 32 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 32 Sex: F Population Size: 1 Sources: Page: p.51 |
Hypoxia | 50% | 800 ug single, sublingual Higher than recommended Dose: 800 ug Route: sublingual Route: single Dose: 800 ug Sources: Page: p.13, 14 |
healthy, 33.4 n = 8 Health Status: healthy Age Group: 33.4 Sex: M+F Population Size: 8 Sources: Page: p.13, 14 |
Nausea | 75% | 800 ug single, sublingual Higher than recommended Dose: 800 ug Route: sublingual Route: single Dose: 800 ug Sources: Page: p.13, 14 |
healthy, 33.4 n = 8 Health Status: healthy Age Group: 33.4 Sex: M+F Population Size: 8 Sources: Page: p.13, 14 |
Somnolence | 87.5% | 800 ug single, sublingual Higher than recommended Dose: 800 ug Route: sublingual Route: single Dose: 800 ug Sources: Page: p.13, 15 |
healthy, 33.4 n = 8 Health Status: healthy Age Group: 33.4 Sex: M+F Population Size: 8 Sources: Page: p.13, 15 |
Vomiting | 50% | 800 ug single, sublingual Higher than recommended Dose: 800 ug Route: sublingual Route: single Dose: 800 ug Sources: Page: p.13, 16 |
healthy, 33.4 n = 8 Health Status: healthy Age Group: 33.4 Sex: M+F Population Size: 8 Sources: Page: p.13, 16 |
Dry mouth | 1.5% Disc. AE |
1600 ug 1 times / 15 min multiple, sublingual (max) Highest studied dose Dose: 1600 ug, 1 times / 15 min Route: sublingual Route: multiple Dose: 1600 ug, 1 times / 15 min Sources: Page: p.309 |
unhealthy, 53±12 n = 65 Health Status: unhealthy Condition: Pain Age Group: 53±12 Sex: M+F Population Size: 65 Sources: Page: p.309 |
Hallucinations | 1.5% Disc. AE |
1600 ug 1 times / 15 min multiple, sublingual (max) Highest studied dose Dose: 1600 ug, 1 times / 15 min Route: sublingual Route: multiple Dose: 1600 ug, 1 times / 15 min Sources: Page: p.309 |
unhealthy, 53±12 n = 65 Health Status: unhealthy Condition: Pain Age Group: 53±12 Sex: M+F Population Size: 65 Sources: Page: p.309 |
Headache | 1.5% Disc. AE |
1600 ug 1 times / 15 min multiple, sublingual (max) Highest studied dose Dose: 1600 ug, 1 times / 15 min Route: sublingual Route: multiple Dose: 1600 ug, 1 times / 15 min Sources: Page: p.309 |
unhealthy, 53±12 n = 65 Health Status: unhealthy Condition: Pain Age Group: 53±12 Sex: M+F Population Size: 65 Sources: Page: p.309 |
Nausea | 1.5% Disc. AE |
1600 ug 1 times / 15 min multiple, sublingual (max) Highest studied dose Dose: 1600 ug, 1 times / 15 min Route: sublingual Route: multiple Dose: 1600 ug, 1 times / 15 min Sources: Page: p.309 |
unhealthy, 53±12 n = 65 Health Status: unhealthy Condition: Pain Age Group: 53±12 Sex: M+F Population Size: 65 Sources: Page: p.309 |
Vomiting | 1.5% Disc. AE |
1600 ug 1 times / 15 min multiple, sublingual (max) Highest studied dose Dose: 1600 ug, 1 times / 15 min Route: sublingual Route: multiple Dose: 1600 ug, 1 times / 15 min Sources: Page: p.309 |
unhealthy, 53±12 n = 65 Health Status: unhealthy Condition: Pain Age Group: 53±12 Sex: M+F Population Size: 65 Sources: Page: p.309 |
Dizziness | 3% Disc. AE |
1600 ug 1 times / 15 min multiple, sublingual (max) Highest studied dose Dose: 1600 ug, 1 times / 15 min Route: sublingual Route: multiple Dose: 1600 ug, 1 times / 15 min Sources: Page: p.309 |
unhealthy, 53±12 n = 65 Health Status: unhealthy Condition: Pain Age Group: 53±12 Sex: M+F Population Size: 65 Sources: Page: p.309 |
Somnolence | 3% Disc. AE |
1600 ug 1 times / 15 min multiple, sublingual (max) Highest studied dose Dose: 1600 ug, 1 times / 15 min Route: sublingual Route: multiple Dose: 1600 ug, 1 times / 15 min Sources: Page: p.309 |
unhealthy, 53±12 n = 65 Health Status: unhealthy Condition: Pain Age Group: 53±12 Sex: M+F Population Size: 65 Sources: Page: p.309 |
Miosis | Disc. AE | 5 mg single, intravenous Accidental dose Dose: 5 mg Route: intravenous Route: single Dose: 5 mg Sources: Page: p.199 |
unhealthy, 62 n = 1 Health Status: unhealthy Condition: Pain Age Group: 62 Sex: M Population Size: 1 Sources: Page: p.199 |
Sweating | Disc. AE | 5 mg single, intravenous Accidental dose Dose: 5 mg Route: intravenous Route: single Dose: 5 mg Sources: Page: p.199 |
unhealthy, 62 n = 1 Health Status: unhealthy Condition: Pain Age Group: 62 Sex: M Population Size: 1 Sources: Page: p.199 |
Visual hallucinations | Disc. AE | 5 mg single, intravenous Accidental dose Dose: 5 mg Route: intravenous Route: single Dose: 5 mg Sources: Page: p.199 |
unhealthy, 62 n = 1 Health Status: unhealthy Condition: Pain Age Group: 62 Sex: M Population Size: 1 Sources: Page: p.199 |
Confusion | acute Disc. AE |
5 mg single, intravenous Accidental dose Dose: 5 mg Route: intravenous Route: single Dose: 5 mg Sources: Page: p.199 |
unhealthy, 62 n = 1 Health Status: unhealthy Condition: Pain Age Group: 62 Sex: M Population Size: 1 Sources: Page: p.199 |
Restlessness | mild Disc. AE |
5 mg single, intravenous Accidental dose Dose: 5 mg Route: intravenous Route: single Dose: 5 mg Sources: Page: p.199 |
unhealthy, 62 n = 1 Health Status: unhealthy Condition: Pain Age Group: 62 Sex: M Population Size: 1 Sources: Page: p.199 |
Opioid abuse | Disc. AE | 200 ug 6 times / day multiple, sublingual Recommended Dose: 200 ug, 6 times / day Route: sublingual Route: multiple Dose: 200 ug, 6 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Pain Sources: Page: p.1 |
Respiratory depression | grade 4 Disc. AE |
200 ug 6 times / day multiple, sublingual Recommended Dose: 200 ug, 6 times / day Route: sublingual Route: multiple Dose: 200 ug, 6 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Pain Sources: Page: p.1 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
likely | ||||
no | ||||
no | ||||
weak | ||||
weak | ||||
weak | ||||
weak | ||||
yes [IC50 117.7 uM] | ||||
yes [IC50 46.2 uM] | ||||
yes [IC50 6.5 uM] | ||||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
likely | ||||
likely | ||||
Page: (Pharm) 17, 28, (PMDA) 17 |
major | yes (co-administration study) Comment: Rate: 61 pmol/min/mg protein; Activity (Fentanyl): 1.03 nmol/min/nmol CYP (Biochem Pharmacol, 53, 1613 (1997)); Coadministartion of Ritonavir (strong CYP3A inhibitor, PO) increased Fentanyl (IV) AUCinf by 2.74-fold. Page: (Pharm) 17, 28, (PMDA) 17 |
||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
no | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Seizure and electroencephalographic changes in the newborn period induced by opiates and corrected by naloxone infusion. | 1999 Mar |
|
Generalized muscle rigidity in a neonate following intrathecal fentanyl during caesarean delivery. | 1999 Nov |
|
Combined spinal epidural for labour analgesia--duration, efficacy and side effects of adding sufentanil or fentanyl to bupivacaine intrathecally vs plain bupivacaine. | 1999 Oct |
|
Continuous paravertebral extrapleural infusion for post-thoracotomy pain management. | 1999 Oct |
|
Three cases with different presentation of fentanyl-induced muscle rigidity--a rare problem in intensive care of neonates. | 2000 |
|
Patient-controlled intranasal analgesia: effective alternative to intravenous PCA for postoperative pain relief. | 2000 Apr |
|
Comparison of intravenous and oral ketoprofen for postoperative pain after adenoidectomy in children. | 2000 Aug |
|
Acute adverse reaction to fentanyl in a 55 year old man. | 2000 Aug |
|
Phenytoin, midazolam, and naloxone protect against fentanyl-induced brain damage in rats. | 2000 Dec |
|
Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. | 2000 Feb |
|
Low-dose clonidine and neostigmine prolong the duration of intrathecal bupivacaine-fentanyl for labor analgesia. | 2000 Feb |
|
A direct search procedure to optimize combinations of epidural bupivacaine, fentanyl, and clonidine for postoperative analgesia. | 2000 Feb |
|
Inhibition by neuropeptide Y of fentanyl-induced muscular rigidity at the locus coeruleus in rats. | 2000 Feb 25 |
|
Minidose bupivacaine-fentanyl spinal anesthesia for surgical repair of hip fracture in the aged. | 2000 Jan |
|
Anaesthetic agents inhibit gastrin-stimulated but not basal histamine release from rat stomach ECL cells. | 2000 Jun |
|
Fentanyl-induced chest wall rigidity and laryngospasm in preterm and term infants. | 2000 Mar |
|
An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. | 2000 Oct |
|
A comparison of minidose lidocaine-fentanyl and conventional-dose lidocaine spinal anesthesia. | 2000 Oct |
|
Computerised advice on drug dosage to improve prescribing practice. | 2001 |
|
A highly automated 96-well solid phase extraction and liquid chromatography/tandem mass spectrometry method for the determination of fentanyl in human plasma. | 2001 |
|
Abuse of topical analgesic. | 2001 Apr |
|
Patient-controlled spinal analgesia for labour and caesarean delivery. | 2001 Feb |
|
When should diclofenac be given in ambulatory surgery: preoperatively or postoperatively? | 2001 Feb |
|
Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. | 2001 Feb |
|
Influence of hemorrhagic shock on remifentanil: a pharmacokinetic and pharmacodynamic analysis. | 2001 Feb |
|
Cardiovascular effects of sevoflurane, isoflurane, halothane, and fentanyl-midazolam in children with congenital heart disease: an echocardiographic study of myocardial contractility and hemodynamics. | 2001 Feb |
|
Epidural fentanyl markedly improves thoracic epidural analgesia in a low-dose infusion of bupivacaine, adrenaline and fentanyl. A randomized, double-blind crossover study with and without fentanyl. | 2001 Feb |
|
Intestinal inflammation enhances the inhibitory effects of opioids on intestinal permeability in mice. | 2001 Feb |
|
Postoperative sleep disturbance: influences of opioids and pain in humans. | 2001 Feb 1 |
|
The metabolic evidence of synergistic effect between ohmefentanyl and [D-Pen2, D-Pen5] enkephalin on differentiated SH-SY5Y cells in humans. | 2001 Feb 9 |
|
Pre-emptive efficacy of epidural fentanyl in elective abdominal surgery. | 2001 Jan |
|
A comparison of remifentanil and fentanyl in patients undergoing carotid endarterectomy. | 2001 Jan |
|
Strong opioids for cancer pain. | 2001 Jan |
|
High concentration sevoflurane induction of anesthesia accelerates onset of vecuronium neuromuscular blockade. | 2001 Jan |
|
[Anesthesia for emergency surgery in a patient with Shy-Drager syndrome]. | 2001 Jan |
|
[Low concentration/high volume is more effective than high concentration/low volume for postoperative continuous epidural analgesia with the combination of bupivacaine and fentanyl]. | 2001 Jan |
|
Digitally assisted acromioplasty: the effect of interscalene block on this new surgical technique. | 2001 Jan |
|
The influence of halothane, isoflurane and sevoflurane on rocuronium infusion in children. | 2001 Jan |
|
Opiates, intracranial pressure, and autoregulation. | 2001 Jan |
|
The Combitube in elective surgery: a report of 200 cases. | 2001 Jan |
|
Buprenorphine substitution ameliorates spontaneous withdrawal in fentanyl-dependent rat pups. | 2001 Jan |
|
Demographic and therapeutic determinants of pain reactivity in very low birth weight neonates at 32 Weeks' postconceptional Age. | 2001 Jan |
|
Awake craniotomy for removal of intracranial tumor: considerations for early discharge. | 2001 Jan |
|
Dexamethasone facilitates discharge after outpatient anorectal surgery. | 2001 Jan |
|
A randomized, double-blinded comparison of intrathecal morphine, sufentanil and their combination versus IV morphine patient-controlled analgesia for postthoracotomy pain. | 2001 Jan |
|
Ultrarapid opioid detoxification: effects on cardiopulmonary physiology, stress hormones and clinical outcomes. | 2001 Jan 1 |
|
Surgery of the canine vagina and vulva. | 2001 Mar |
|
Opiate self-administration as a measure of chronic nociceptive pain in arthritic rats. | 2001 Mar |
|
Neural circuits regulating pulsatile luteinizing hormone release in the female guinea-pig: opioid, adrenergic and serotonergic interactions. | 2001 Mar |
|
Morphine and alternative opioids in cancer pain: the EAPC recommendations. | 2001 Mar 2 |
Sample Use Guides
Dosage should be individualized. Some of the factors to be considered in determining the dose are age, body weight,
physical status, underlying pathological condition, use of other drugs, type of anesthesia to be used and the surgical
procedure involved. Dosage should be reduced in elderly or debilitated patients (see PRECAUTIONS).
Vital signs should be monitored routinely.
I. Premedication — Premedication (to be appropriately modified in the elderly, debilitated and those who
have received other depressant drugs) — 50 to 100 mcg (0.05 to 0.1 mg) (1 to 2 mL) may be
administered intramuscularly 30 to 60 minutes prior to surgery.
II. Adjunct to General Anesthesia — See Dosage Range Chart
III. Adjunct to Regional Anesthesia - 50 to 100 mcg (0.05 to 0.1 mg) (1 to 2 mL) may be administered
intramuscularly or slowly intravenously, over one to two minutes, when additional analgesia is
required.
IV. Postoperatively (recovery room) - 50 to 100 mcg (0.05 to 0.1 mg) (1 to 2 mL) may be administered
intramuscularly for the control of pain, tachypnea and emergence delirium. The dose may be repeated
in one to two hours as needed
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26770358
0.5 - 5 ng/ml fentanyl inhibited viability of SW1990 cells in vitro.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:45:50 GMT 2023
by
admin
on
Sat Dec 16 17:45:50 GMT 2023
|
Record UNII |
UF599785JZ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN01AH51
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
||
|
NCI_THESAURUS |
C67413
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
||
|
NDF-RT |
N0000175684
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
||
|
LIVERTOX |
NBK548026
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
||
|
CFR |
21 CFR 524.916
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
||
|
WHO-VATC |
QN02AB03
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
||
|
WHO-ATC |
N01AH01
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
||
|
WHO-VATC |
QN02AB53
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
||
|
NDF-RT |
N0000175690
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
||
|
WHO-ATC |
N01AH51
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
||
|
WHO-ATC |
N02AB03
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
||
|
WHO-VATC |
QN02AB73
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
||
|
WHO-VATC |
QN01AH01
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
EFFENTORA (AUTHORIZED: PAIN)
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
||
|
DEA NO. |
9801
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
PECFENT (AUTHORIZED: PAIN)
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
||
|
NCI_THESAURUS |
C1506
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3345
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
119915
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
CHEMBL596
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
DTXSID9023049
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
4337
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | RxNorm | ||
|
UF599785JZ
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
D005283
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
3329
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
UF599785JZ
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
SUB07597MIG
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
100000090377
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
Fentanyl
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
SS-102
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
1626
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
207-113-6
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
DB00813
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
1608
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
437-38-7
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
RECUVYRA [AUTHORIZED]
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | DOGS | ||
|
m5298
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | Merck Index | ||
|
1164
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
1269902
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
C494
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY | |||
|
FENTANYL
Created by
admin on Sat Dec 16 17:45:54 GMT 2023 , Edited by admin on Sat Dec 16 17:45:54 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
DERIVATIVE -> PARENT |
|
||
|
CUMULATIVE EXCRETION |
URINE
|
||
|
PRECURSOR->PARENT |
|
||
|
TARGET -> AGONIST |
HUMAN RECEPTOR
AGONIST
Ki
|
||
|
PRECURSOR->PARENT |
|
||
|
PRECURSOR->PARENT |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Possible deadly drug interaction with CYP3A4 inhibitors
MAJOR
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
OFF TARGET->NON-INHIBITOR |
|
||
|
TARGET -> AGONIST |
AGONIST
EC50
|
||
|
OFF TARGET->NON-INHIBITOR |
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
PARENT -> DERIVATIVE |
|
||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
CUMULATIVE EXCRETION |
FECAL
|
||
|
EXCRETED UNCHANGED |
FECAL; URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE ACTIVE -> PARENT |
|
||
|
METABOLITE INACTIVE -> PARENT |
|
||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
Relative Response Factor - 1.0
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
ED50(mg/kg) = 0.0061, LD50(mg/kg) = 62, Potency ratio to morphine = 54.1, Potency ratio to fentanyl = 1
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||